An update from Aldeyra Therapeutics (ALDX) is now available.
Aldeyra Therapeutics, Inc. has announced the appointment of Michael Alfieri as the new principal financial officer and principal accounting officer, effective August 31, 2024. Alfieri, who brings extensive experience from previous roles in biopharmaceutical companies like Genocea Biosciences and Radius Health, will operate under a consulting agreement through Danforth Global, Inc. Concurrently, Bruce Greenberg will depart from his executive roles at Aldeyra and has agreed to a separation package which includes salary continuation, a lump-sum payment, and consulting services that allow for the vesting of his stock options.
For an in-depth examination of ALDX stock, go to TipRanks’ Stock Analysis page.
